Latest Investments News

SSH Group Limited reported a 7% revenue decline and a 21% drop in profit after tax for FY2025, while net tangible assets per share doubled amid strategic acquisitions.

333D Ltd has reported a remarkable financial turnaround in FY2025, posting a 426% revenue increase and its first profit after tax, driven by its digital asset management strategy.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

Avecho Biotechnology reported a 79% revenue increase driven by a $4.8 million upfront licensing fee from Sandoz, yet its half-year loss grew 23% as R&D and administrative costs rose. The company advances its Phase III CBD insomnia trial while pursuing further international licensing.

Imugene Limited has successfully closed its Share Purchase Plan, raising $2.42 million following a $22.5 million institutional placement, reinforcing its capital position for ongoing immuno-oncology development.

Energy Technologies Limited reported a $11 million net loss for FY2025, reflecting a strategic pivot and ongoing capital challenges. Despite a 37% revenue drop, management highlights operational resilience and plans to stabilise through capital management.

hummgroup reports a robust 57% increase in FY25 cash profit to $52.9 million, driven by asset growth and operational efficiencies, while navigating regulatory changes and elevated credit losses.

Hummgroup Limited reported a robust FY25 with cash profit soaring to $52.9 million, a significant reduction in costs, and a maintained historically low credit loss ratio. The group also completed a full repayment of its Perpetual Notes, signaling improved capital efficiency.

Aeris Resources has delivered a standout FY25 performance, posting a 78% rise in EBITDA and a 286% surge in net profit, driven by strong commodity prices and disciplined cost management.

Alternative Investment Trust (ASX, AIQ) reported a robust half-year profit increase of 183%, driven by strong gains in its Warana-managed portfolio. The Trust also announced a significant $44.6 million rights issue to fund further investments.

Clarity Pharmaceuticals reported a $64.3 million loss for FY2025 alongside significant clinical progress and a $203.6 million placement to fund its radiopharmaceutical pipeline expansion.

The Agency Group has delivered a record financial performance in FY2025, with Gross Commission Income surpassing $125 million, driven by strong growth in residential sales and property management. The company’s unique national direct agency model and strategic expansion into emerging markets underpin its positive outlook.